In this article, we will take a look at the 5 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. For a deeper discussion and an extended list, please see the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen.

5. Bristol-Myers Squibb Company (NYSE:BMY)

Point72 Asset Management: $162,041,747

On April 30, 2026, Reuters reported that Bristol-Myers Squibb Company (NYSE:BMY) announced first-quarter adjusted earnings of $1.58 per share, which came in above analysts’ average estimate of $1.42. The revenue of $11.49 billion also exceeded expectations of $10.9 billion. Shares rose by 4%.

Eliquis produced $4.14 billion in quarterly sales with growth of 16% YoY. Chief Commercialization Officer Adam Lenkowsky said that demand continues to be solid, with new prescription share over 75%, adding that the drug’s performance should support growth later this year. Bristol-Myers Squibb Company (NYSE:BMY)’s growth portfolio, which includes cell therapy Breyanzi and Camzyos, went up by 12% to $6.23 billion. This made up more than half of the total revenue.

Opdivo sales declined 5% to $2.15 billion and missed projections of $2.33 billion. CFO David Elkins said that the shortfall is because of wholesaler inventory cutbacks, and the company is still watching whether levels return to normal.

Trung Huynh, an analyst at RBC Capital Markets, believes second-half catalysts, such as the probable approval of a next-generation cancer therapy and late-stage milvexian data, are more important than current quarterly results.

The company reiterated its sales outlook for 2026 of $46.0 billion to $47.5 billion, trending toward the higher end.

Bristol-Myers Squibb Company (NYSE:BMY) is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It provides small molecules, biologics, and CAR-T cell treatments.

4. Repligen Corporation (NASDAQ:RGEN)

Point72 Asset Management: $164,893,957

On May 7, Barclays raised Repligen Corporation (NASDAQ:RGEN)’s price goal to $160 from $145. It maintained an “Overweight rating” on the stock.

On April 17, 2026, Repligen Corporation (NASDAQ:RGEN) officially opened its third Training & Innovation Center at its OPUS Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The site adds to the company’s existing centers in Waltham, Massachusetts, and Tokyo, Japan.

According to CEO Olivier Loeillot, the Breda center provides workshops for technical teams and customers, while also showcasing the company’s vast and diversified bioprocessing portfolio. The facility highlights Repligen Corporation’s entire bioprocessing technology portfolio. It included upstream intensification tools like XCell ATF and KrosFlo TFDF devices, along with downstream offerings like OPUS chromatography columns, Spectrum hollow fiber filters, capital equipment systems, and fluid management products.

Loeillot noted that the inauguration, together with previous investments in the Asia Pacific and the United States, reflects Repligen Corporation (NASDAQ:RGEN)’s commitment to serving customers globally.

Repligen Corporation (NASDAQ:RGEN) is a global life sciences firm that provides bioprocessing technologies and solutions for the manufacture of biological drugs. It operates throughout North America, Europe, the Asia-Pacific Region, and other geographic areas.

3. AstraZeneca PLC (NYSE:AZN)

Point72 Asset Management: $170,322,480

AstraZeneca PLC (NYSE:AZN) is among the Best Biotech Stocks.

On May 1, CNBC reported that an FDA advisory panel voted 6-3 against allowing AstraZeneca PLC (NYSE:AZN)’s oral breast cancer drug camizestrant. This action resulted in the company’s London-listed shares falling 2% Friday morning.

Panel members voting against the drug concluded that the SERENA-6 study failed to show that early switching to camizestrant helped with long-term survival compared to existing therapies. Although it raised no serious concerns about the drug’s toxicity or safety.

Barclays analyst James Gordon said that the issue remains complicated, with the panel never dismissing camizestrant’s efficacy or future potential. It simply found SERENA-6 insufficient to justify the shift in clinical practice. Jefferies analysts agreed, saying the group saw the impact as minor and uncertain. Jefferies added that SERENA-6 made up only a minor portion of AstraZeneca PLC (NYSE:AZN)’s $80 billion sales goal for 2030 and that the vote was merely a sentimental hit.

AstraZeneca PLC (NYSE:AZN) Executive Vice President Susan Galbraith said that the firm is highly committed to camizestrant and will continue to cooperate with the FDA during its review.

AstraZeneca PLC (NYSE:AZN) is a multinational biopharmaceutical firm. It works in the research, development, and marketing of prescription medicines.

2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Point72 Asset Management: $202,636,715

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the Best Biotech Stocks.

On April 23, Reuters reported that the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s gene treatment for a rare genetic form of deafness. It is the first gene therapy for genetic hearing loss. The firm stated that the therapy, Otarmeni, will be given away for free to American patients through the FDA’s priority voucher program.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) produced the therapy to treat Otoferlin-related hearing loss caused by OTOF gene variations. This affects 20 to 50 babies each year. The pharmaceutical firm explained that the treatment delivers the missing protein by delivering a working copy of the OTOF gene through a modified virus infused into the cochlea.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s auditory global program head, Jonathon Whitton, told Reuters that the approval marks “a new era” in hearing loss treatment. Reuters stated that competitors such as Eli Lilly are researching comparable treatments that have shown early success.

Sierra, the mother of a study participant, told Reuters that the therapy helped her child respond to his name. She called the development “the craziest thing.”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology firm. It works in the discovery, invention, development, manufacturing, and marketing of pharmaceuticals. Its brand lineup includes Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

1.  Biogen Inc. (NASDAQ:BIIB)

Point72 Asset Management’s Stake Value: $495,093,660

Biogen Inc. (NASDAQ:BIIB) is the Best Biotech Stock. 

On April 20, 2026, Reuters reported that Biogen Inc. (NASDAQ:BIIB) had agreed to pay up to $850 million for the exclusive Greater China rights to felzartamab. It is an experimental immune therapy developed by Chinese biotech TJ Biopharma, bringing the drug’s global commercial coverage to a close.

TJ Biopharma will receive $100 million up front. It will also add up to $750 million in milestone payments and further royalties on Greater China sales. Biogen Inc. (NASDAQ:BIIB) shares rose 1.3% in premarket trading.

Felzartamab is currently in the last stage trials for IgA nephropathy and primary membranous nephropathy. These are two kidney diseases that can lead to organ failure. China’s health regulator is separately assessing the drug for multiple myeloma.

Biogen Inc. (NASDAQ:BIIB) obtained felzartamab as part of its $1.8 billion takeover of Human Immunology Biosciences in 2024. In April 2025, the two companies launched the partnership in China. If authorities approve the medicine, Biogen Inc. (NASDAQ:BIIB) plans to oversee regional manufacture and commercialization. TJ Biopharma continues to produce it at its Hangzhou facility for myeloma.

Biogen Inc. (NASDAQ:BIIB) is a biopharmaceutical firm that works on identifying, making, and providing drugs for neurological and neurodegenerative diseases.

READ NEXT: 12 Best Photonics Stocks to Buy Now and 8 Best European Industrial Stocks to Buy Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.